Lymphodepleting

DRUG2 trials

Conditions

Breast Cancer (Advanced/Metastatic)HER2-positive Breast CancerLymphoma, Non-HodgkinPrecursor Cell Lymphoblastic Leukemia-LymphomaTriple-negative Breast Cancer

Phase 1

A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL)

TerminatedNCT03743246

CelgeneLymphoma, Non-Hodgkin, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Start: 2018-10-17End: 2024-01-26Updated: 2024-08-15

Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC

RecruitingNCT07510802

Beijing BiotechBreast Cancer (Advanced/Metastatic), HER2-positive Breast Cancer, Triple-negative Breast Cancer

Start: 2026-02-02End: 2028-04-17Target: 60Updated: 2026-04-06

Lymphodepleting

Sponsors

Conditions

Phase 1